文献速递心力衰竭与心肌病心律失常

分钟通气量靶向自适应伺服通气对心力衰竭心血管结局的影响:CAT-HF试验

Cardiovascular Outcomes With Minute Ventilation-Targeted Adaptive Servo-Ventilation Therapy in Heart Failure: The CAT-HF Trial.
PubMed 文献 · J Am Coll Cardiol · 2017-01-01

CAT-HF试验将住院心力衰竭合并中重度睡眠呼吸暂停患者随机分配至自适应伺服通气(ASV)联合优化药物治疗(OMT)组或单纯OMT对照组,主要终点为6个月全球排名复合评分。ASV组呼吸暂停低通气指数较对照组显著降低,但主要终点两组无显著差异;预设亚组分析提示射血分数保留的心力衰竭患者可能获益,但研究把握度有限,需进一步研究。

要点

  • ASV联合OMT未改善住院心衰合并中重度睡眠呼吸暂停患者6个月心血管复合结局。
  • ASV组呼吸暂停低通气指数从35.7次/小时降至2.1次/小时,对照组从35.1次/小时降至19.0次/小时(p<0.0001)。
  • 预设亚组分析提示射血分数保留的心衰患者可能从ASV获益(p=0.036),但研究把握度有限。

核心结论

  • 在住院心力衰竭合并中重度睡眠呼吸暂停患者中,在优化药物治疗基础上加用ASV未改善6个月心血管结局。
  • 研究把握度有限,不足以检测安全性信号或识别射血分数保留的心力衰竭患者中ASV的差异效应,但该人群需要进一步研究。

研究设计与样本

  • CAT-HF试验将住院心力衰竭合并中重度睡眠呼吸暂停的合格患者随机分配至ASV联合优化药物治疗组或单纯优化药物治疗对照组。
  • 计划入组215例,实际随机126例;SERVE-HF试验结果公布后提前终止入组。
  • 主要终点为6个月全球排名复合评分,层级依次为死亡、心血管住院和6分钟步行距离百分比变化。

主要发现

  • ASV组平均设备使用时间为每晚2.7小时。
  • 6个月时ASV组呼吸暂停低通气指数平均事件数从35.7次/小时降至2.1次/小时,对照组从35.1次/小时降至19.0次/小时(p<0.0001)。
  • 主要终点在ASV组与对照组之间无显著差异(p=0.92,Wilcoxon检验)。
  • 复合终点各组分的变化在ASV组与对照组之间无显著差异。
  • 治疗与射血分数之间无显著交互作用(p=0.10,Cox模型);预设亚组分析提示射血分数保留的心力衰竭患者中ASV可能有益(p=0.036)。

临床怎么用

  • 原文结论为在住院心力衰竭合并中重度睡眠呼吸暂停患者中,优化药物治疗加用ASV未改善6个月心血管结局。
  • 原文指出研究把握度有限,但射血分数保留的心力衰竭人群需要进一步研究。

局限性

  • 计划入组215例,实际仅随机126例,入组因SERVE-HF试验结果公布而提前终止。
  • 研究把握度有限,不足以检测安全性信号或识别射血分数保留的心力衰竭患者中ASV的差异效应。
  • 原文结论指出射血分数保留的心力衰竭人群需要进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Sleep apnea is common in hospitalized heart failure (HF) patients and is associated with increased morbidity and mortality. OBJECTIVES: The CAT-HF (Cardiovascular Improvements With MV-ASV Therapy in Heart Failure) trial investigated whether minute ventilation (MV) adaptive servo-ventilation (ASV) improved cardiovascular outcomes in hospitalized HF patients with moderate-to-severe sleep apnea. METHODS: Eligible patients hospitalized with HF and moderate-to-severe sleep apnea were randomized to ASV plus optimized medical therapy (OMT) or OMT alone (control). The primary endpoint was a composite global rank score (hierarchy of death, cardiovascular hospitalizations, and percent changes in 6-min walk distance) at 6 months. RESULTS: 126 of 215 planned patients were randomized; enrollment was stopped early following release of the SERVE-HF (Adaptive Servo-Ventilation for Central Sleep Apnea in Systolic Heart Failure) trial results. Average device usage was 2.7 h/night. Mean number of events measured by the apnea-hypopnea index decreased from 35.7/h to 2.1/h at 6 months in the ASV group versus 35.1/h to 19.0/h in the control group (p < 0.0001). The primary endpoint did not differ significantly between the ASV and control groups (p = 0.92 Wilcoxon). Changes in composite endpoint components were not significantly different between ASV and control. There was no significant interaction between treatment and ejection fraction (p = 0.10 Cox model); however, pre-specified subgroup analysis suggested a positive effect of ASV in patients with HF with preserved ejection fraction (p = 0.036). CONCLUSIONS: In hospitalized HF patients with moderate-to-severe sleep apnea, adding ASV to OMT did not improve 6-month cardiovascular outcomes. Study power was limited for detection of safety signals and identifying differential effects of ASV in patients with HF with preserved ejection fraction, but additional studies are warranted in this population. (Cardiovascular Improvements With MV ASV Therapy in Heart Failure [CAT-HF]; NCT01953874).

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. O'Connor CM, Whellan DJ, Fiuzat M, et al. Cardiovascular Outcomes With Minute Ventilation-Targeted Adaptive Servo-Ventilation Therapy in Heart Failure: The CAT-HF Trial. J Am Coll Cardiol. 2017. PMID: 28335841. doi:10.1016/j.jacc.2017.01.041

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。